Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647

Eur J Pharmacol. 2007 Jul 2;566(1-3):117-9. doi: 10.1016/j.ejphar.2007.03.007. Epub 2007 Mar 19.

Abstract

The analgesic properties of cannabinoid receptor agonists are well characterized. However, numerous side effects limit the therapeutic potential of these agents. Here we report a synergistic antinociceptive interaction between the endogenous cannabinoid receptor agonist anandamide and the synthetic peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist 2-(4-(2-(1-Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid (GW7647) in a model of acute chemical-induced pain. Moreover, we show that anandamide synergistically interacts with the large-conductance potassium channel (KCa1.1, BK) activator isopimaric acid. These findings reveal a synergistic interaction between the endocannabinoid and PPAR-alpha systems that might be exploited clinically and identify a new pharmacological effect of the BK channel activator isopimaric acid.

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Arachidonic Acids / pharmacology*
  • Behavior, Animal / drug effects
  • Butyrates / pharmacology*
  • Cannabinoid Receptor Agonists*
  • Drug Synergism
  • Endocannabinoids
  • Formaldehyde
  • Male
  • Mice
  • PPAR alpha / agonists*
  • Pain / chemically induced
  • Pain / drug therapy
  • Pain / physiopathology
  • Phenylurea Compounds / pharmacology*
  • Polyunsaturated Alkamides / pharmacology*

Substances

  • Analgesics
  • Arachidonic Acids
  • Butyrates
  • Cannabinoid Receptor Agonists
  • Endocannabinoids
  • GW 7647
  • PPAR alpha
  • Phenylurea Compounds
  • Polyunsaturated Alkamides
  • Formaldehyde
  • anandamide